OGEN

Oragenics

• Seeking Alpha·1d ago

  Oragenics gets until February 2028 to regain NYSE listing compliance

• TipRanks·09/16 15:00

  Oragenics Highlights Nasal Innovation at Industry Forum

• TipRanks·08/28 21:36

  Oragenics Faces NYSE Compliance Challenges Amid Trial Progress

• Dow Jones·08/28 20:31

  *Oragenics: Received a Deficiency Letter From NYSE Amer LLC Notifying the Co It Is Not in Compliance With Continued Listing Standards >OGEN

• Dow Jones·08/28 20:31

  *Oragenics: Received Responses From FDA Related to Its Type B Meeting Request Briefing Package, Submitted in July >OGEN

• Dow Jones·08/28 20:31

  *Oragenics: Reviewing These Items and Remains Focused on Submitting an Investigational New Drug Application by the End 2026 >OGEN

• Dow Jones·08/28 20:31

  *Oragenics: Remains Focused on Execution Across Clinical, Regulatory, Corporate Objectives >OGEN

• Dow Jones·08/28 20:31

  *Oragenics: Continues to Advance ONP-002, Its Lead Intranasal Candidate for mTBI (Concussion), Through Phase IIa Feasibility Trial in Australia >OGEN

• NASDAQ·07/08 06:34

  Oragenics Activates Third Site For Phase 2a Of ONP-002 In Treating Concussions, Data By Q4 '26

• TipRanks·07/06 20:36

  Oragenics Appoints New Chief Financial Officer and Leader

• TipRanks·05/19 12:58

  Oragenics Highlights Investor Outreach at Micro-Cap Conference

• Seeking Alpha·05/18 16:19

  Oragenics reports Q1 results

• NASDAQ·04/21 02:41

  Oragenics Advances Phase IIa Trial Of ONP-002 For Concussion

• TipRanks·04/20 14:01

  Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

• NASDAQ·04/14 08:51

  Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002